<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medical therapy of arrhythmias associated with Wolff-Parkinson-White syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medical therapy of arrhythmias associated with Wolff-Parkinson-White syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medical therapy of arrhythmias associated with Wolff-Parkinson-White syndrome</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Arrhythmia</td> <td class="subtitle1">Treatment options</td> <td class="subtitle1">Contraindicated therapies</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Orthodromic AV reentrant tachycardia</td> </tr> <tr> <td class="indent1">Acute termination*</td> <td> <p><strong>Unstable patients:</strong> Synchronized cardioversion</p> <p><strong>Stable patients:<span class="indent2"></span></strong></p> <ul> <li><span class="indent2"><strong>First line</strong>: Vagal maneuvers</span> </li> <li><span class="indent2"><strong>Second line</strong>: IV adenosine</span> </li> <li><span class="indent2"><strong>Third line</strong>: IV verapamil OR IV diltiazem</span> </li> <li><span class="indent2"><strong>Other therapies</strong>: IV procainamide OR IV beta blocker; synchronized cardioversion if other therapies are ineffective or not feasible</span> </li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Chronic prevention<sup>¶</sup> </td> <td> <p><strong>First line</strong>: Catheter ablation of the accessory pathway</p> <p><strong>Second line</strong>: Oral flecainide or propafenone in the absence of structural or ischemic heart disease</p> <strong>Third line</strong>: Oral IA antiarrhythmic agent OR oral amiodarone</td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Antidromic AV reentrant tachycardia</td> </tr> <tr> <td class="indent1">Acute termination*</td> <td> <p><strong>Unstable patients:</strong> Synchronized cardioversion</p> <p><strong>Stable patients (if CERTAIN of the diagnosis)</strong>: Same progression of therapies as acute termination of orthodromic AVRT<sup>Δ</sup></p> <p><strong>Stable patients (if NOT certain of the diagnosis)</strong>: IV procainamide, synchronized cardioversion if procainamide is ineffective or not available<sup>Δ</sup></p> </td> <td>Adenosine, verapamil, diltiazem, beta blockers, digoxin should all be avoided if NOT certain of diagnosis</td> </tr> <tr class="divider_bottom"> <td class="indent1">Chronic prevention<sup>¶</sup></td> <td> <p><strong>First line</strong>: Catheter ablation of the accessory pathway</p> <p><strong>Second line</strong>: Oral flecainide or propafenone in the absence of structural or ischemic heart disease</p> <p><strong>Other therapies</strong>: Oral IA antiarrhythmic agent OR oral amiodarone</p> </td> <td> <p>Digoxin</p> <p>Beta blockers</p> <p>Verapamil, diltiazem</p> </td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="3">Pre-excited atrial fibrillation</td> </tr> <tr class="divider_bottom"> <td class="indent1"> Acute termination*</td> <td><strong>Unstable patients:</strong> Synchronized cardioversion <p><strong>Stable patients:<span class="indent2"></span></strong></p> <ul> <li><span class="indent2"><strong>First line</strong>: IV ibutilide or IV procainamide</span> </li> <li><span class="indent2"><strong>Other therapies</strong>: IC antiarrhythmic agent or dofetilide; synchronized cardioversion if other therapies are ineffective or not available</span> </li> </ul> </td> <td> <p>Amiodarone</p> <p>Digoxin</p> <p>Beta blockers</p> <p>Adenosine</p> <p>Verapamil, diltiazem</p> </td> </tr> <tr class="divider_bottom"> <td class="indent1"> Chronic prevention<sup><span style="font-size: 13px;">¶</span></sup></td> <td> <p><strong>First line</strong>: Catheter ablation or the accessory pathway</p> <p><strong>Second line</strong>: Oral flecainide or propafenone in the absence of structural or ischemic heart disease</p> <p><strong>Third line</strong>: Oral IA antiarrhythmic agent OR oral amiodarone</p> </td> <td>Oral digoxin</td> </tr> </tbody></table></div><div class="graphic_footnotes">AVRT: atrioventricular reciprocating tachycardia; IV: intravenous; class IC: flecainide, propafenone; class IA: quinidine, procainamide, disopyramide.<br/>* Cardioversion is indicated if hemodynamically unstable or drugs are ineffective.<br/>¶ Ablation of the accessory pathway is generally preferred to cure the arrhythmia.<br/>Δ Procainamide is the intravenous drug of choice for acute termination of suspected antidromic AVRT. If the tachycardia is definitely known to be antidromic AVRT, and it has been verified that the AV node (rather than a second accessory pathway) is acting as the retrograde limb of the circuit, one could consider treatment with an agent such as adenosine similar to therapy for orthodromic AVRT, but it is rare to have all of the necessary data in the acute setting to justify use of AV nodal blocking agents.</div><div id="graphicVersion">Graphic 62762 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
